MediBeacon creates novel light-activated agents to enable medical innovations. A noninvasive real-time kidney function monitoring system is in human clinical trials.
Location: United States, Missouri, Saint Louis
Employees: 11-50
Total raised: $62.4M
Founded date: 2012
Investors 3
Funding Rounds 3
| Date | Series | Amount | Investors |
| 16.11.2022 | - | $10M | - |
| 31.07.2019 | - | $30M | - |
| 27.08.2015 | - | $22.4M | - |
Mentions in press and media 6
| Date | Title | Description |
| 25.02.2025 | MediBeacon® Transdermal GFR System receives device approval in China; Peer-reviewed articles on MediBeacon technology published | Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function. The Clinical Kidney Journal in February published MediBeacon study results on measu... |
| 18.01.2025 | MediBeacon® Transdermal GFR System Receives FDA Approval to Assess Kidney Function | Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function. The transdermal GFR (tGFR) methodology has been designed to be effective across the... |
| 16.11.2022 | MediBeacon Receives $10 Million in Amended Agreements with Huadong Medicine to Accelerate Development of Transdermal GFR Measurement System | MediBeacon approaching completion of Phase 3 study focused on kidney disease; Has submitted three of five required PMA modules needed for FDA approval ST. LOUIS, Nov. 16, 2022 /PRNewswire/ -- MediBeacon Inc., a portfolio company within the ... |
| 31.07.2019 | MediBeacon Announces $30 Million Investment from Huadong Medicine | NEW YORK, July 31, 2019 (GLOBE NEWSWIRE) -- HC2 Holdings, Inc. (NYSE:HCHC), a diversified holding company announced today that MediBeacon Inc., a privately held portfolio company within HC2’s Pansend Life Science announced today that they h... |
| 27.08.2015 | Daily funding roundup - August 27, 2015 | Yuneec bagged $60M; MediBeacon landed $22.4M; Remerge closed $3M Mobile App Retargeting startup Remerge today announced a $3 million Series A round led by Point Nine Capital, along with Valor, VC Fonds Technologie Berlin, German Startups Gr... |
| 27.08.2015 | MediBeacon Receives $22.4M in Financing | MediBeacon TM Inc., a St. Louis-based maker of a proprietary noninvasive real-time monitoring system for kidney function, received $22.4m in financing. Pansend LLC, an indirect wholly owned subsidiary of HC2 Holdings, Inc. (NYSE MKT: HCHC),... |